| Human bone marrow–derived mesenchymal stem cells in the treatment of gliomas A Nakamizo, F Marini, T Amano, A Khan, M Studeny, J Gumin, J Chen, ... Cancer research 65 (8), 3307-3318, 2005 | 1393 | 2005 |
| Bone marrow-derived mesenchymal stem cells as vehicles for interferon-β delivery into tumors M Studeny, FC Marini, RE Champlin, C Zompetta, IJ Fidler, M Andreeff Cancer research 62 (13), 3603-3608, 2002 | 1282 | 2002 |
| Mesenchymal stem cells: potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents M Studeny, FC Marini, JL Dembinski, C Zompetta, M Cabreira-Hansen, ... Journal of the National Cancer Institute 96 (21), 1593-1603, 2004 | 1108 | 2004 |
| Mesenchymal stem cells in cancer: tumor-associated fibroblasts and cell-based delivery vehicles B Hall, J Dembinski, AK Sasser, M Studeny, M Andreeff, F Marini International journal of hematology 86, 8-16, 2007 | 238 | 2007 |
| Tumor stroma engraftment of gene-modified mesenchymal stem cells as anti-tumor therapy against ovarian cancer JL Dembinski, SM Wilson, EL Spaeth, M Studeny, C Zompetta, I Samudio, ... Cytotherapy 15 (1), 20-32. e2, 2013 | 88 | 2013 |
| Reduction of nontarget infection and systemic toxicity by targeted delivery of conditionally replicating viruses transported in mesenchymal stem cells JL Dembinski, EL Spaeth, J Fueyo, C Gomez-Manzano, M Studeny, ... Cancer gene therapy 17 (4), 289-297, 2010 | 81 | 2010 |
| Nintedanib for the treatment of patients with refractory metastatic colorectal cancer (LUME-Colon 1): a phase III, international, randomized, placebo-controlled study E Van Cutsem, T Yoshino, HJ Lenz, S Lonardi, A Falcone, ML Limón, ... Annals of Oncology 29 (9), 1955-1963, 2018 | 62 | 2018 |
| Effect of small angiokinase inhibitor nintedanib (BIBF 1120) on QT interval in patients with previously untreated, advanced renal cell cancer in an open-label, phase II study T Eisen, Y Shparyk, N Macleod, R Jones, G Wallenstein, G Temple, ... Investigational new drugs 31, 1283-1293, 2013 | 57 | 2013 |
| Metabolism of a [18F] fluorine labeled progestin (21-[18F] fluoro-16α-ethyl-19-norprogesterone) in humans: a clue for future investigations A Verhagen, M Studeny, G Luurtsema, GM Visser, CCJ De Goeij, ... Nuclear medicine and biology 21 (7), 941-952, 1994 | 53 | 1994 |
| A phase I/II, open-label, randomised study of nintedanib plus mFOLFOX6 versus bevacizumab plus mFOLFOX6 in first-line metastatic colorectal cancer patients E Van Cutsem, H Prenen, G D'haens, J Bennouna, A Carrato, M Ducreux, ... Annals of Oncology 26 (10), 2085-2091, 2015 | 42 | 2015 |
| Local production and/or delivery of anti-cancer agents by stromal cell precursors M Studeny, M Andreeff, F Marini US Patent App. 10/377,276, 2004 | 41 | 2004 |
| A phase l/lI, open-label, randomised study of BIBF 1120 plus mFOLFOX6 compared to bevacizumab plus mFOLFOX6 in patients with metastatic colorectal cancer E Van Cutsem, H Prenen, C Guillen-Ponce, J Bennouna, M Di Benedetto, ... European Journal of Cancer, 8-9, 2011 | 32 | 2011 |
| Vascular effects, efficacy and safety of nintedanib in patients with advanced, refractory colorectal cancer: a prospective phase I subanalysis K Mross, M Büchert, A Frost, M Medinger, P Stopfer, M Studeny, R Kaiser BMC cancer 14, 1-10, 2014 | 31 | 2014 |
| Phase I trial of the DLL3/CD3 bispecific T-cell engager BI 764532 in DLL3-positive small-cell lung cancer and neuroendocrine carcinomas M Wermke, E Felip, V Gambardella, Y Kuboki, D Morgensztern, ... Future Oncology 18 (24), 2639-2649, 2022 | 29 | 2022 |
| A multicentre, open-label, phase-I/randomised phase-II study to evaluate safety, pharmacokinetics, and efficacy of nintedanib vs. sorafenib in European patients with advanced … DH Palmer, YT Ma, M Peck-Radosavljevic, P Ross, J Graham, L Fartoux, ... British journal of cancer 118 (9), 1162-1168, 2018 | 28 | 2018 |
| Phase II efficacy and safety study of nintedanib versus sunitinib in previously untreated renal cell carcinoma (RCC) patients. T Eisen, Y Shparyk, R Jones, NJ MacLeod, G Temple, H Finnigan, ... Journal of Clinical Oncology 31 (15_suppl), 4506-4506, 2013 | 27 | 2013 |
| Rationale and design for the LUME-Colon 1 study: a randomized, double-blind, placebo-controlled phase III trial of nintedanib plus best supportive care versus placebo plus best … E Van Cutsem, T Yoshino, J Hocke, Z Oum'Hamed, M Studeny, ... Clinical Colorectal Cancer 15 (1), 91-94. e1, 2016 | 22 | 2016 |
| First-in-human dose-escalation trial of BI 764532, a delta-like ligand 3 (DLL3)/CD3 IgG-like T-cell engager in patients (pts) with DLL3-positive (DLL3+) small-cell lung cancer … M Wermke, E Felip, Y Kuboki, D Morgensztern, C Sayehli, MF Sanmamed, ... Journal of Clinical Oncology 41 (16_suppl), 8502-8502, 2023 | 18 | 2023 |
| Nintedanib plus best supportive care (BSC) versus placebo plus BSC for the treatment of patients (pts) with colorectal cancer (CRC) refractory to standard therapies: results of … E Van Cutsem, T Yoshino, HJ Lenz, S Lonardi, A Falcone, ML Limon, ... Annals of Oncology 27, 2016 | 11 | 2016 |
| OA01. 05 Phase I Dose Escalation Trial Of The DLL3/CD3 Igg-Like T Cell Engager BI 764532 In Patients with DLL3+ Tumors: Focus on SCLC M Wermke, Y Kuboki, E Felip, OB Alese, D Morgensztern, C Sayehli, ... Journal of Thoracic Oncology 18 (11), S45-S46, 2023 | 8 | 2023 |
Jennifer L DembinskiNorwegian Institute of Public Health, Department of Virology在 fhi.no 的电子邮件经过验证
Jennifer L DembinskiNorwegian Institute of Public Health, Department of Virology在 fhi.no 的电子邮件经过验证